Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyVlado Perkovic, Kenneth W. Mahaffey, Meg Jardine et al.|New England Journal of Medicine|2019Cited by 6k
Dapagliflozin in Patients with Chronic Kidney DiseaseHiddo J.L. Heerspink, David C. Wheeler, Bergur V. Stefánsson et al.|New England Journal of Medicine|2020Cited by 5.2k
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysisCaroline S. Fox, Robert G. Nelson, Kunihiro Matsushita et al.|The Lancet|2012Cited by 1.4k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney DiseaseDick de Zeeuw, Glenn M. Chertow, Tadao Akizawa et al.|New England Journal of Medicine|2013Cited by 990
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsColin Baigent, Faı̈ez Zannad, Jonathan Emberson et al.|The Lancet|2022Cited by 969